Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease

…, S Gräber, E Kuder-Buletta, C LaFougere, C Laske… - Nature medicine, 2019 - nature.com
Neurofilament light chain (NfL) is a promising fluid biomarker of disease progression for
various cerebral proteopathies. Here we leverage the unique characteristics of the Dominantly …

White matter hyperintensities are a core feature of Alzheimer's disease: evidence from the dominantly inherited Alzheimer network

…, JM Ringman, NS Ryan, S Förster, C Laske… - Annals of …, 2016 - Wiley Online Library
Objective White matter hyperintensities (WMHs) are areas of increased signal on T2‐weighted
magnetic resonance imaging (MRI) scans that most commonly reflect small vessel …

Innovative diagnostic tools for early detection of Alzheimer's disease

C Laske, HR Sohrabi, SM Frost, K López-de-Ipiña… - Alzheimer's & …, 2015 - Elsevier
… Author links open overlay panel Christoph Laske a b , Hamid R. Sohrabi c d , Shaun M. Frost
e f , Karmele López-de-Ipiña g , Peter Garrard h , Massimo Buscema i j , Justin Dauwels k , …

BDNF serum and CSF concentrations in Alzheimer's disease, normal pressure hydrocephalus and healthy controls

C Laske, E Stransky, T Leyhe, GW Eschweiler… - Journal of psychiatric …, 2007 - Elsevier
Alzheimer’s disease (AD) and normal pressure hydrocephalus (NPH) are common forms of
dementia in the elderly. Recent findings have suggested an involvement of brain-derived …

Safety and efficacy of semorinemab in individuals with prodromal to mild Alzheimer disease: a randomized clinical trial

…, T Grimmer, ME Kottke-Arbeiter, C Laske… - JAMA …, 2022 - jamanetwork.com
Importance Neurofibrillary tangles composed of aggregated tau protein are one of the
neuropathological hallmarks of Alzheimer disease (AD) and correlate with clinical disease severity…

[HTML][HTML] Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research

…, T Foroud, M Carrillo, N Graff-Radford, C Laske… - Alzheimer's & …, 2015 - Elsevier
The lack of readily available biomarkers is a significant hindrance toward progressing to
effective therapeutic and preventative strategies for Alzheimer's disease (AD). Blood-based …

Antidepressant effects of augmentative transcranial magnetic stimulation: randomised multicentre trial

…, B Haya, T Kammer, B Langguth, C Laske… - The British Journal of …, 2007 - cambridge.org
BackgroundRepetitive transcranial magnetic stimulation (rTMS) has been proposed as a new
treatment option for depression. Previous studies were performed with low sample sizes in …

Exercise-induced normalization of decreased BDNF serum concentration in elderly women with remitted major depression

C Laske, S Banschbach, E Stransky… - International Journal …, 2010 - academic.oup.com
Major depression (MD) has been associated with decreased brain-derived neurotrophic
factor (BDNF) serum levels, while antidepressant drugs were found to increase these …

Higher BDNF serum levels predict slower cognitive decline in Alzheimer's disease patients

C Laske, K Stellos, N Hoffmann… - International Journal …, 2011 - academic.oup.com
The neurotrophin brain-derived neurotrophic factor (BDNF) plays a critical role in neuronal
survival, synaptic plasticity, and memory. Several recent studies have demonstrated altered …

[HTML][HTML] 24-month intervention with a specific multinutrient in people with prodromal Alzheimer's disease (LipiDiDiet): a randomised, double-blind, controlled trial

…, D Ramelli, L Frölich, L Hausner, C Laske… - The Lancet …, 2017 - thelancet.com
Background Nutrition is an important modifiable risk factor in Alzheimer's disease. Previous
trials of the multinutrient Fortasyn Connect showed benefits in mild Alzheimer's disease …